Dupilumab improves Health-related quality of life among COPD patients: Study

A new study published in the Chest Journal showed that Dupilumab helps individuals with type 2 inflammation and chronic obstructive pulmonary disease (COPD) in improving their health-related quality of life (HRQoL). A major contributing factor to mortality in chronic obstructive pulmonary disease is a diminished quality of life. And, dupilumab inhibits the common receptor component for interleukin (IL)-4 and IL-13, which are important and fundamental causes of type 2 inflammation in a variety of illnesses. In patients with COPD and type 2 inflammation (blood eosinophil count ≥300 cells/µL) who had an elevated risk of exacerbations despite inhaled triple therapy, add-on dupilumab 300 mg every two weeks (q2w) significantly decreased the rate of moderate or severe exacerbations and improved lung function when compared to a matched placebo in the phase 3 BOREAS and NOTUS trials.

The phase 3 randomized studies, BOREAS and NOTUS, evaluated the safety and effectiveness of subcutaneous add-on dupilumab 300 mg or placebo every two weeks in patients on triple treatment who had moderate-to-severe airflow limitation, COPD, and type 2 inflammation. For this study, data from primary analysis of both trials' populations were combined. A patient-reported outcomes measure of health-related quality of life in respiratory diseases is the St. George's Respiratory Questionnaire (SGRQ). The SGRQ total score and specific domain scores (symptoms, effects, and activities) at week 52 were the endpoints, and they were measured against baseline.

Dupilumab or a placebo was administered at random to the participants. The mean baseline SGRQ total score of Dupilumab was 50.3, whereas the placebo's was 49.5. Dupilumab and placebo had mean symptoms domain ratings of 59.3 vs. 58.6, mean activity scores of 66.3 vs. 65.8, and mean effect domain scores of 38.2 vs. 37.3, respectively. The least-squares mean difference against placebo at Week 52.

Individual SGRQ domain mean scores at week 52 showed similar improvements, as did the mean symptoms domain score, which showed a mean difference versus placebo from baseline to week 52, the mean activity domain score, which showed a mean difference versus placebo from baseline to Week 52 of -3.997, and the mean impact domain score, which showed a mean difference against placebo from baseline to week 52 of -2.870. Overall, in the pooled analysis of two phase 3 clinical trials of individuals with COPD and type 2 inflammation, this analysis found dupilumab to increase HRQoL as evaluated by the SGRQ in the overall score and all categories when compared with placebo.

Source:

BHATT, S. P., RABE, K. F., HANANIA, N. A., VOGELMEIER, C., BAFADHEL, M., CHRISTENSON, S., PAPI, A., SINGH, D., LAWS, E., DAKIN, P., MALONEY, J., LU, X., BAUER, D., BANSAL, A., ABDULAI, R., & ROBINSON, L. (2024). DUPILUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND TYPE 2 INFLAMMATION: POOLED BOREAS AND NOTUS RESULTS. In CHEST (Vol. 166, Issue 4, pp. A4826–A4830). Elsevier BV. https://doi.org/10.1016/j.chest.2024.06.2869